Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.

NCT01658826 is registered in ClinicalTrials.gov with AiCuris Anti-infective Cures AG as lead sponsor.

NCT NCT01658826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01658826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Lead sponsor
AiCuris Anti-infective Cures AG
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2012
Completion date
July 31, 2013
Enrollment
91 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

genital herpes